NCT07014826
A Trial of HRS-5965 Capsule in Primary IgA Nephropathy
StatusActive, Not Recruiting
PhasePhase 3
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 26 words Show 4 more changesShow less
- Enrollment closed, study ongoing
- Enrollment target: estimated 378 to confirmed 389
- Secondary endpoints: details revised at 2 of 8 entries
- Site details revised
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Start date changed from estimate of Jun 2025 to Jun 4, 2025
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Ratio of 24-hour Urinary protein to creatinine ratio (UPCR) to baseline
Timeframe: Baseline and Week 36
The total annualized slope of estimated glomerular filtration rate(eGFR)
Timeframe: Baseline and Week 104
Secondary (8)
The total annualized slope of estimated glomerular filtration rate(eGFR)
Proportion of subjects with 24-hour urinary protein excretion (24-UPE) < 0.5 g/d and < 0.3 g/d
Proportion of subjects with 24-UPCR declined >50% to baseline
Ratio of 24-hour Urinary protein to creatinine ratio (24-UPCR) to baseline
Ratio of 24-hour Urinary protein to Albumin Creatinine ratio (24-UACR) to baseline
Show 3 moreShow less
Ratio of 24-hour Urinary protein excretion(24-UPE) to baseline
Change from baseline of eGFR
Change from baseline of serum creatinine
Arms and interventions
Treatment group AExperimental
HRS-5965
Treatment group BPlacebo comparator
Placebo
Drugs: HRS-5965, Placebo
Sites
1 site in 1 country
- Peking University First HospitalBeijing, Beijing Municipality, China